Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6732066 | 0.85 | CYP3A4 (0.41) | HDAC4HDAC6OPRM1OPRD1OPRK1 | |
| SCHEMBL6736614 | 0.83 | MME (0.39) | OPRM1OPRD1OPRK1CYP3A4MAPK1 | |
| SCHEMBL27538252 | 0.83 | LPAR1 (0.50) | KMT2APAM | |
| SCHEMBL6896981 | 0.83 | LPAR1 (0.50) | KMT2APAM | |
| SCHEMBL7214805 | 0.81 | TACR1 (0.38) | TACR1SIGMAR1MEN1KMT2A | |
| SCHEMBL27543517 | 0.81 | LPAR1 (0.48) | HDAC6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6891444 | 0.81 | LPAR1 (0.48) | HDAC6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6898352 | 0.81 | LPAR1 (0.48) | HDAC6MEN1NPC1RAB9AKMT2A | |
| SCHEMBL6895814 | 0.81 | CTSS (0.42) | KMT2A | |
| SCHEMBL6898127 | 0.80 | MMP1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683200-B2 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE IS USED AS A TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORY AGENT AND A THERAPEUTICAL AGENT FOR AUTOIMMUNE DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-01-27 | — | — | US | claimed |
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-06 | — | — | US | claimed |
| EP-1172358-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | claimed |
| US-6683200-B2 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE IS USED AS A TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORY AGENT AND A THERAPEUTICAL AGENT FOR AUTOIMMUNE DISEASES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| EP-1172358-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
| JP-2000351761-A | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE, AND MEDICINAL COMPOSITION CONTAINING THE SAME | SANTEN PHARMACEUT CO LTD | 2000-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068763-A1 | N-substituted-N'-substituted urea derivatives and pharmaceutical compositions containing the derivatives | TNF, NFKBIA, UMPS | HDAC4 2744/4885HDAC6 863/4885OPRM1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.